Patient Square Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Patient Square Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-350,000	Closed	-$4.23M	–	30
2025 Q4	$4.23M	Buy	350,000 +33,688	+11%	+$458K	0.91%	25
2025 Q3	$4.3M	Buy	+316,312	New	+$2.98M	1.15%	18

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Patient Square Capital's AMLX Position: Q1 2026 in Review

Patient Square Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 350,000 shares — an estimated $4.23M sold.

Patient Square Capital first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $4.3M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Patient Square Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Patient Square Capital sold 350,000 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $4.23M.
Patient Square Capital first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Patient Square Capital's Amylyx Pharmaceuticals position peaked at $4.3M in Q3 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.